Synergistic effect of intervention of glypican-3 gene transcription combined with antitumor drugs in inhibiting hepatoma cell proliferation
-
摘要: 目的探讨干预磷脂酰肌醇蛋白多糖(GPC)3基因转录和联合抗肿瘤药物对肝癌细胞增殖的抑制效果。方法构建4种GPC-3-shRNA质粒转染肝癌HepG2细胞,以realtime-PCR、Western Blot法观察GPC-3基因及蛋白表达水平,分析其与肝癌细胞增殖、凋亡的关系。计量资料两组间比较采用独立样本t检验,多组间比较采用单因素方差分析。结果 4种转染质粒中shRNA1转染HepG2细胞效率>85%,在mRNA水平的沉默效率为89.3%,GPC-3蛋白表达显著抑制(P<0.01)。shRNA1干扰组72 h HepG2细胞抑制率71.1%,与阴性组比较差异有统计学意义(t=18.092,P<0.001);shRNA1干扰组肝癌细胞发生生物学特性改变,迁移抑制率为89.1%,明显慢于阴性组,差异有统计学意义(t=8.326,P<0.001);HepG2细胞运动抑制率为53.6%、侵袭抑制率60.1%,与阴性组比较差异均有统计学意义(t值分别为52.400、48.245,P值均<0.001)。shRNA1干扰组β-catenin mRNA抑制率为46.9%...
-
关键词:
- 肝肿瘤 /
- 磷脂酰肌醇蛋白聚糖类 /
- 抗肿瘤药 /
- 基因,抑制 /
- 药物协同作用
Abstract: Objective To investigate the inhibitory effect of intervention of glypican- 3( GPC3) gene transcription combined with antitumor drugs on hepatoma cell proliferation. Methods Four types of GPC3- shRNA plasmids were established and transfected into HepG2 hepatoma cells. Quantitative real- time PCR and Western blot were used to measure the mRNA and protein expression of GPC3 to analyze its association with hepatoma cell proliferation and apoptosis. The independent samples t- test was used for comparison of continuous data between any two groups,and a one- way analysis of variance was used for comparison between multiple groups. Results Among these four plasmids,shRNA1 had a transfection efficiency of > 85% in the transfection of HepG2 cells and a silence efficiency of 89. 3% at the mRNA level,and the protein expression of GPC3 was significantly inhibited( P < 0. 01). At 72 hours,the GPC3- shRNA1 co- intervention group had an HepG2 cell inhibition rate of 71. 1%,significantly different from that in the negative group( t = 18. 092,P < 0. 001),an inhibition rate of migration of 89. 1%,significantly lower than that in the negative group( t = 8. 326,P < 0. 001),and inhibition rates of HepG2 cell movement and invasion of 53. 6% and 60. 1%,which were significantly different from those in the negative group( t = 52. 400 and 48. 245,both P < 0. 001). The GPC3- shRNA1 co- intervention group had a β- catenin mRNA inhibition rate of 46. 9% and a Gli1 mRNA upregulation rate of 7. 4%,significantly different from those in the negative group( t = 30. 108 and- 3. 551,P < 0. 001 and P = 0. 009). At 24 hours,10 μmol/L sorafenib combined with shRNA1 had an inhibition rate of tumor cells of 52. 6% and 100 μmol/L sorafenib combined with shRNA1 had an inhibition rate of tumor cells of 79. 5%,which were significantly different from that in the control group( t = 23. 314 and50. 352,both P < 0. 001). The half- maximal inhibitory concentrations of sorafenib,rapamycin,and erlotinib for HepG2 were 4. 67 ± 1. 20μmol/L,7. 85 ± 2. 00 nmol/L,and 18. 36 ± 0. 56 μmol/L,respectively,and their combination with shRNA1 had an HepG2 cell inhibition rate of 95. 11%. Conclusion Intervention of GPC3 gene transcription with specific shRNA can inhibit hepatoma cell proliferation,migration and movement,and invasion ability,induce hepatoma cell apoptosis,and inhibit hepatoma cell proliferation when combined with antitumor drugs in a synergistic manner. This suggests that GPC3 may be an effective therapeutic target for liver cancer and that combined targeted therapy can provide better strategies for the treatment of liver cancer.-
Key words:
- liver neoplasms /
- glypicans /
- antineoplastic agents /
- genes,suppressor /
- drug synergism
-
[1]BRUIX J,GORES GJ,MAZZAFERRO V.Hepatocellular carcinoma:clinical frontiers and perspectives[J].Gut,2014,63(5):844-885. [2]EL-SERAG HB.Hepatocellular carcinoma[J].N Engl J Med,2011,365(12):1118-1127. [3]LAI JP,OSEINI AM,MOSER CD,et al.The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation[J].Hepatology,2010,52(5):1680-1689. [4]WANG L,YAO M,DONG ZZ,et al.Circulating specific biomarkers in diagnosis of hepato-cellular carcinoma and its metastasis monitoring[J].Tumor Biol,2014,35(1):9-20. [5]VILCHEZ V,TURCIOS L,MARTI F,et al.Targeting Wnt/β-catenin pathway in hepato-cellular carcinoma treatment[J].World J Gastroenterol,2016,22(2):823-832. [6]DUCHARTRE Y,KIM YM,KAHN M.The Wnt signaling pathway in cancer[J].Crit Rev Oncol Hematol,2016,99(1):141-149. [7] YAO M,WANG L,SHI Y,et al.Intervention of glypican-3 genetic transcription on anti-proliferative effect of hepatoma cells with high metastatic potentiality[J].Natl Med J China,2014,94(32):2544-2548.(in Chinese)姚敏,王理,时运,等.干预GPC-3基因转录对高转移潜能肝癌细胞的增殖抑制作用[J].中华医学杂志,2014,94(32):2544-2548. [8]TONG HV,BOCK CT,VELAVAN TP.Genetic insights on host and hepatitis B virus in liver diseases[J].Mutat Res Rev Mutat Res,2014,762(1):65-75. [9]BRUIX J,SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology,2011,53(3):1020-1022. [10]ZHU PL,YIN C,FENG JL.Progress in comprehensive treatment of primary liver cancer[J].J Clin Hepatol,2015,31(6):965-968.(in Chinese)祝普利,尹超,冯建龙.原发性肝癌综合治疗进展[J].临床肝胆病杂志,2015,31(6):965-968. [11]KANDIL DH,COOPER K.Glypican-3:a novel diagnostic marker for hepatocellular carcinoma and more[J].Adv Anat Pathol,2009,16(2):125-129. [12]YAO M,YAO DF,BIAN YZ,et al.Oncofetal antigen glypican-3as a promising early diagnostic marker for hepatocellular carcinoma[J].Hepatobiliary Pancreat Dis Int,2011,10(3):289-294. [13]YU DD,DONG ZZ,YAO M,et al.Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA[J].Tumor Biol,2013,34(2):661-668. [14]PEZ F,LOPEZ A,KIM M,et al.Wnt signaling and hepatocarcinogenesis:molecular targets for the development of innovative anticancer drugs[J].J Hepatol,2013,59(5):1107-1117. [15]ZHANG HJ,YAO DF,YAO M,et al.Silencing ANXA2 on effects of MHCC97-H cell invasion and tumorigenic potential[J].World J Gastroenterol,2013,19(24):3792-3801. [16]BOILY G,OUELLET S,LANGLOIS S,et al.In vivo footprinting analysis of the Glypican 3(GPC3)promoter region in neuroblastoma cells[J].Biochim Biophys Acta,2007,1769(3):182-193. [17]UMEZU T,SHIBATA K,KAJIYAMA H,et al.Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary[J].J Clin Pathol,2010,63(11):962-966. [18]CAPURRO MI,SHI W,FILMUS J.LRP1 mediates Hedgehog-induced endocytosis of the GPC3-Hedgehog complex[J].J Cell Sci,2012,125(Pt 14):3380-3389. [19]CHEN J,YAO M,YAO DF.Role of glypican-3 signaling pathways and therapeutic potential in hepatocellular carcinoma[J].J Clin Hepatol,2013,29(1):77-81.(in Chinese)陈洁,姚敏,姚登福.磷脂酰肌醇蛋白多糖-3介导的信号通路与肝癌靶向治疗[J].临床肝胆病杂志,2013,29(1):77-81.
本文二维码
计量
- 文章访问数: 1984
- HTML全文浏览量: 47
- PDF下载量: 405
- 被引次数: 0